



NDA 019901/S-060

SUPPLEMENT APPROVAL

Pfizer, Inc.
Attention: Sheetal Alur
Senior Manager, Worldwide Regulatory Strategy
235 East 42nd Street
New York, NY 10017

Dear Ms. Alur:

Please refer to your Supplemental New Drug Application (sNDA) dated and received February 22, 2013, submitted under section 505(b)(1) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Altace (ramipril) 1.25 mg, 2.5 mg, 5 mg, and 10 mg, .

This "Prior Approval" supplemental new drug application provides for labeling revised as follows (additions are marked as underlined text and deletions are marked as ~~strikethrough text~~):

1. In **HIGHLIGHTS/RECENT MAJOR CHANGES**, the following text was added/deleted:

Boxed Warning: Fetal Toxicity	04/2012
Contraindications	09/2013
<u>Warnings and Precautions: Anaphylactoid and Possibly Related Reactions (5.1)</u>	<u>09/2013</u>
Warnings and Precautions: Fetal Toxicity (5.6)	04/2012
<u>Warnings and Precautions: Dual Blockade of the Renin-Angiotensin-Aldosterone System (5.7)</u>	<u>09/2013</u>

2. In **HIGHLIGHTS/CONTRAINDICATIONS**, the following text was added:

Do not co-administer aliskiren with ALTACE in patients with diabetes or in patients with renal impairment (GFR < 60 mL/min/1.73 m²). (4)

3. In **HIGHLIGHTS/WARNINGS AND PRECAUTIONS**, the following text was added:

Angioedema, with increased risk in patients with a prior history (5.1) or when combined with mTOR inhibitors (5.1)

4. In **HIGHLIGHTS/DRUG INTERACTIONS**, the following text was added:

mTOR inhibitor use may increase angioedema risk (7.7)

5. Under **CONTRAINDICATIONS**, the following text was added:

Do not co-administer aliskiren with ALTACE in patients with diabetes or in patients with renal impairment (GFR < 60 mL/min/1.73 m²).

6. Under **WARNINGS AND PRECAUTIONS/ Anaphylactoid and Possibly Related Reactions**, the following text was added as the sixth paragraph:

Patients taking concomitant mTOR inhibitor (e.g. temsirolimus) therapy may be at increased risk for angioedema. [see Drug Interactions (7.7)]

7. Under **WARNINGS AND PRECAUTIONS/ Dual Blockade of the Renin-Angiotensin-Aldosterone System**, the following text was added:

Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. Closely monitor blood pressure, renal function and electrolytes in patients on ALTACE and other agents that affect the RAS.

Aliskiren

Do not co-administer aliskiren with ALTACE in patients with diabetes or in patients with renal impairment (GFR <60 mL/min/1.73 m²). [see Drug Interactions (7.6)]

8. Under **DRUG INTERACTIONS**, the following sections were added:

7.6 Aliskiren

Do not co-administer aliskiren with ALTACE in patients with diabetes or in patients with renal impairment (GFR <60 mL/min/1.73 m²). [see Warnings and Precautions (5.7)].

7.7 mTOR Inhibitors

Patients taking concomitant mTOR inhibitor (e.g. temsirolimus) therapy may be at increased risk for angioedema. [see Warnings and Precautions (5.1)]

9. Under the Distribution/Manufacturing information at the end of the label, the information was changed from:

~~Distributed by:~~

~~Monarch Pharmaceuticals, Inc.~~

~~Bristol, TN 37620~~

~~(A wholly owned subsidiary of King Pharmaceuticals, Inc.)~~

Manufactured by:

King Pharmaceuticals, Inc.

Bristol, TN 37620

To:



10. The Table of Contents was updated to reflect the addition of new sections.

11. The revision date and version number were updated.

There are no other changes from the last approved package insert.

We have completed our review of this supplemental application, and it is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert), with the addition of any labeling changes in pending "Changes Being Effectuated" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit the following, in triplicate, (1) a cover letter requesting advisory comments, (2) the proposed materials in draft or mock-up form with annotated references, and (3) the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Division of Drug Marketing, Advertising, and Communications
5901-B Ammendale Road
Beltsville, MD 20705-1266

You must submit final promotional materials and package insert(s), accompanied by a Form FDA 2253, at the time of initial dissemination or publication [21 CFR 314.81(b)(3)(i)]. Form FDA 2253 is available at <http://www.fda.gov/opacom/morechoices/fdaforms/cder.html>; instructions are provided on page 2 of the form. For more information about submission of promotional materials to the Division of Drug Marketing, Advertising, and Communications (DDMAC), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

All promotional materials that include representations about your drug product must be promptly revised to be consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 314.70(a)(4)]. The revisions in your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 314.70(a)(4) to the address above or by fax to 301-847-8444.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call:

Lori Anne Wachter, RN, BSN
Regulatory Project Manager for Safety
(301) 796-3975

Sincerely,

{See appended electronic signature page}

Mary Ross Southworth, PharmD.
Deputy Director for Safety
Division of Cardiovascular and Renal Products
Office of Drug Evaluation 1
Center for Drug Evaluation and Research

ENCLOSURE:
Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARY R SOUTHWORTH
09/23/2013